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PURPOSE. To evaluate the effectiveness of a single intravitreal injection of dexamethasone
implant, over 6 months in patients with recalcitrant CME due to Irvine-Gass syndrome.
METHODS. Retrospective review of the medical records of nine patients with refractory
macular edema (ME) due to Irvine-Gass syndrome, who underwent a single intravitreal
injection of dexamethasone implant, Ozurdex, between November 2010 and January 2012, at
the Instituto de Microcirurgia Ocular, Barcelona, Spain. All patients underwent a complete
ophthalmic evaluation, including best-corrected visual acuity (BCVA) using standardized
ETDRS charts, tonometry, fluorescein angiography, and spectral-domain optical coherence
tomography with foveal thickness (FT) measurement.
RESULTS. The mean duration of CME before treatment with Ozurdex was 9.1 months (range, 6–
13 months). At baseline, the mean FT was 542.22 6 134.78 lm. Mean (SD) values of FT did
decrease to 350.88 6 98.71 lm (P ¼ 0.001) at month 1 and 319.22 6 60.96 lm (P ¼ 0.002)
at month 3. Data on the 6-month follow-up showed a mild increase 398.33 6 127.89 lm (P ¼
0.031). The mean (SD) change from baseline FT was 191.33 lm (a decrease value of 35%) at
month 1, and 223.00 lm (decrease value of 41%) and 143.89 lm (decrease value of 26%) at
month 3 and month 6, respectively. The baseline BCVA data were 0.62 6 0.15 logarithm of
the minimum angle of resolution (logMAR). The mean BCVA improved to 0.47 6 0.21
logMAR (P ¼ 0.008) and 0.37 6 0.24 logMAR (P ¼ 0.001) after month 1 and month 3,
respectively. At the last visit (6-month follow-up), the mean BCVA was 0.37 6 0.26 logMAR (P
¼ 0.002).
CONCLUSIONS. In this study, both mean FT and mean BCVA had improved from baseline by 1
month after treatment with a dexamethasone implant, and the improvement remained
statistically significant throughout the 6-month study.
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In 1953, Irvine described a CME that specifically arose aftercataract surgery.1 Gass and Norton subsequently studied the
characteristics of the new disease entity with fluorescein
angiography.2,3 Irvine-Gass syndrome is still recognized as one
of the most common causes of poor visual outcome following
cataract surgery.4,5
The pathogenesis of pseudophakic CME is thought to be
multifactorial. However, the major etiology appears to be
inflammatory mediators that are upregulated in the aqueous
and vitreous humors after surgical manipulation. Inflammation
breaks down the blood-aqueous and blood-retinal-barriers,
which leads to increased vascular permeability.6 Eosinophilic
transudate accumulates in the outer plexiform and inner
nuclear layers of the retina to create cystic spaces that coalesce
to form larger pockets of fluid.1 In chronic CME, lamellar
macular holes and subretinal fluid may also form.
Despite treatment options for Irvine-Gass syndrome, which
include nonsteroidal anti-inflammatory drugs, corticosteroids,
and acetazolamide, and new fields of clinical research including
the use of antivascular endothelial growth factor agents,
resistant cases of macular edema are common.7,8
Glucocorticoids such as dexamethasone exert their anti-
inflammatory effects by influencing multiple signal transduc-
tion pathways, including VEGF.9–12 By binding to cytoplasmic
glucocorticoid receptors, corticosteroids in high doses increase
the activation of anti-inflammatory genes, whereas at low
concentrations they have a role in the suppression of activated
inflammatory genes.10–13
The dexamethasone implant (Ozurdex; Allergan, Inc.,
Irvine, CA) is a novel approach approved by the United States
Food and Drug Administration (FDA) and by the European
Union (EU) for the intravitreal treatment of macular edema
(ME) after branch or central retinal vein occlusion and for the
treatment of noninfectious uveitis affecting the posterior
segment of the eye.14 Furthermore, clinical efficacy has been
documented in other diseases, such as diabetic macular edema
(DME) and persistent macular edema (ME) associated with
uveitis or Irvine-Gass syndrome.15–20 Compared with published
data describing other routes of administration of dexametha-
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sone analogues, several results demonstrate a few advantages
of this implant.21 Key features of the drug delivery system are
the sustained-release formulation of the poly(lactic acid-co-
glycolic acid) (PLGA) matrix material, which dissolves com-
pletely in vivo, and the single-use applicator for intravitreal
placement.22
The primary purpose of this study was to evaluate the
effectiveness of a single intra-vitreal injection of Ozurdex
(Allergan, Inc.), over 6 months in patients with persistent CME
resulting from Irvine-Gass syndrome.
SUBJECTS AND METHODS
We retrospectively reviewed the medical records of nine
patients with decreased visual acuity resulting from chronic
pseudophakic CME, refractory to topical, periocular, systemic,
and intravitreal treatments, who underwent a single injection
of Ozurdex (Allergan, Inc.) between November 2010 and
January 2012 at the Instituto de Microcirurgia Ocular,
Barcelona, Spain.
Key inclusion criteria included having previously under-
gone a wide range of treatment options including oral carbonic
anhydrase inhibitors (CAIs), topical combination therapy with
nonsteroidal anti-inflammatory drugs (NSAIDs) and corticoste-
roids, as well as intravitreal treatment either with anti-VEGF
agents or with intravitreal triamcinolone. Refractory ME was
defined as persistent ME with foveal thickness (FT) of 250 lm
by spectral-domain optical coherence tomography (SD-OCT),
lasting for at least 90 days after intravitreal anti-VEGF/steroid
treatment.
Exclusion criteria included diagnosis of uncontrolled
systemic disease, glaucoma, elevated IOP, and epiretinal
membrane or vitreomacular traction in the study eye that
could prevent improvement in visual acuity, as well as any
intraocular injection, intraocular surgery, or laser treatment in
the study eye within the previous 3 months. Informed consent
was obtained from all patients in accordance with the
Declaration of Helsinki for research involving human subjects.
At baseline, all patients underwent a complete ophthalmic
evaluation, including best-corrected visual acuity (BCVA) using
standardized ETDRS charts, tonometry, fluorescein angiogra-
phy, and SD-OCT (Cirrus HD-OCT; Carl Zeiss Meditec, Inc.,
Dublin, CA) with FT measurement. Patients received a
dexamethasone implant in the study eye at the baseline visit
(day 1). A single-use applicator with a 22-gauge needle was
used to place a dexamethasone implant in the vitreal chamber
through a self-sealing scleral injection. All injections were
performed in the operating room.
All patients returned to our institution at regular intervals
after the surgical procedure for ocular and systemic follow-up.
Patients were seen at outcome assessment study visits at day 2
and at months 1, 3, and 6. All patients were monitored for any
local or systemic adverse effects during the entire study.
The primary efficacy outcome measure was the change
from baseline in BVCA and in FT from baseline to month 6.
Statistical calculations were performed using the Statistical
Package for Social Sciences (version 20.0; SPSS Inc., Chicago,
IL). Mean changes from baseline FT and BCVA (converted to
the logarithm of the minimum angle of resolution [logMAR])
were analyzed using paired t-tests. A 2-tailed test with an a
level of 0.05 was used for all comparisons. We report our
results herein.
RESULTS
During the inclusion period of the study, persistent ME due to
pseudophakic CME was identified in nine patients who had
undergone dexamethasone implant. Baseline characteristics of
patients and study eyes are listed in the Table. The patients’
mean age was 67.3 6 15.8 years and 66% (six of nine patients)
were women.
All patients had undergone a wide range of treatments
previously including oral carbonic anhydrase inhibitors (CAIs),
topical combination therapy with NSAIDs and corticosteroids,
as well as intravitreal treatment either with anti-VEGF agents or
with intravitreal triamcinolone. The mean duration of CME
before treatment with Ozurdex (Allergan, Inc.) was 9.1 months
(range, 6–13 months).
At baseline, the mean FT was 542.22 6 134.78 lm. Mean
(SD) values of FT did decrease to 350.88 6 98.71 lm (P ¼
0.001) at month 1 and 319.22 6 60.96 lm (P ¼ 0.002) at
month 3. Data from the 6-month follow-up showed a mild
increase 398.33 6 127.89 lm (P ¼ 0.031). All of the FT
reduction outcomes were statistically significant, with respect
to baseline data (P < 0.05). The mean (SD) change from
baseline FT was 191.33 lm (a decrease value of 35%) at month
1, and 223.00 lm (decrease value of 41%) and 143.89 lm
(decrease value of 26%) at month 3 and month 6, respectively
(Fig. 1).
Statistically significant improvement in BCVA also was seen
at month 1 after treatment with a dexamethasone implant and
at each subsequent follow-up visit (Fig. 2). The baseline BCVA
data were 0.62 6 0.15 logMAR. The mean BCVA improved to
TABLE. Baseline Demographics and Clinical Features of Study Eye
Patient















Baseline FT, Month 1 FT, Month 3 FT, Month 6
1 F 37 8 0.70 0.70 0.70 0.70 563.00 278.00 281.00 487.00
2 M 83 12 0.80 0.50 0.50 0.50 662.00 541.00 371.00 697.00
3 F 56 8 0.50 0.40 0.10 0.10 573.00 467.00 407.00 371.00
4 F 66 6 0.80 0.80 0.70 0.70 764.00 363.00 256.00 310.00
5 F 64 11 0.50 0.40 0.40 0.40 405.00 285.00 243.00 367.00
6 F 65 7 0.50 0.10 0.10 0.00 601.00 282.00 273.00 264.00
7 M 67 8 0.70 0.50 0.40 0.50 533.00 319.00 320.00 356.00
8 M 76 9 0.40 0.30 0.10 0.10 465.00 381.00 396.00 401.00
9 F 92 13 0.70 0.50 0.30 0.30 314.00 242.00 326.00 332.00
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0.47 6 0.21 logMAR (P¼ 0.008), and 0.37 6 0.24 logMAR (P¼
0.001) after 1 and 3 months, respectively. At the last visit (6-
month follow-up), the mean BCVA remained the approximate
value 0.37 6 0.26 logMAR (P ¼ 0.002).
No anecdotal IOP elevation was observed throughout the
study. No serious ocular or systemic adverse events were
observed.
DISCUSSION
In the current study, intravitreal treatment with a dexameth-
asone implant safely reduced ME and improved visual acuity in
a difficult-to-treat patient population with long-standing ME
owing to Irvine-Gass syndrome.
Both mean FT and mean BCVA had improved from baseline
by 1 month after treatment with a dexamethasone implant, and
the improvement remained statistically significant throughout
the 6-month study. The peak effectiveness of dexamethasone
implants was seen at 3 months after injection, when mean FT
had decreased by 41%, and the mean BCVA improved to 0.37
6 0.24 logMAR from baseline.
So far, there are only a few controlled clinical trials that have
evaluated treatments for ME associated with Irvine-Gass
syndrome, including one on the use of vitrectomy for chronic
aphakic CME.23 Intravitreal triamcinolone (TA) has been
widely studied in DME and retinal vein occlusion, but data
are lacking supporting its use in pseudophakic CME. In 2003,
Benhamou et al. reported the first study using 8 mg intravitreal
triamcinolone to treat three cases of refractory chronic
pseudophakic CME and showed that FT and visual acuity
improved, but the effects were transient.24 Other case series
also report transient benefits using 4 mg intravitreal triamcin-
olone.25–28 Clearly, one of the major limitations of intravitreal
corticosteroids is the transient effect necessitating repeated
injections. This problem can be overcome by the currently
available sustained-release dexamethasone implant.
Most other studies have focused on the treatment of
chronic pseudophakic CME that has been refractory to other
treatments. In 2008, Spitzer et al. showed that 1.25 mg
intravitreal bevacizumab did not significantly improve visual
outcomes in a series of 16 eyes with refractory pseudophakic
CME, although there was a slight decrease in FT.29 ‘‘Triple
therapy’’ with intravitreal triamcinolone, intravitreal bevacizu-
mab, and topical NSAIDs has been shown to be effective as
well, although the effects of the intravitreal medications were
transient.30
Sustained drug delivery systems (DDS) have been devel-
oped to address the limitation of intravitreal corticosteroid
injections. Ozurdex (Allergan, Inc.) is an injectable, biodegrad-
able intravitreal DDS that provides sustained release of
preservative-free dexamethasone, a potent corticosteroid.31
In 2009, the FDA approved its use for treatment of ME
secondary to retinal vein occlusions, and in 2010, it was
approved for noninfectious posterior uveitis.14 A phase II study
subgroup analysis investigated its efficacy in the treatment of
persistent ME resulting from uveitis or pseudophakic CME.32
Twenty-seven patients with refractory pseudophakic CME
were recruited and randomized to receive dexamethasone
DDS 350 lg, dexamethasone DDS 700 lg, or observation. Eight
patients showed at least a 10-letter improvement at day 90 and
maintained the improvement at day 180. Significance testing
was performed with combined data from pseudophakic CME
and uveitis patients: an improvement in BCVA of at least 10
letters at day 90 was seen in 42% in the 350 lm group (P ¼
0.117), and 54% in the 700 lm group (P ¼ 0.029). Another
study is currently enrolling patients for a phase II study to
examine the dexamethasone DDS to treat CME and DME after
cataract surgery.33
Similarly, our data are consistent with those results named
above. Indeed, the dexamethasone implant resulted in
sustained levels of dexamethasone and biological activity for
6 months, with peak levels of drug over the first 3 months.17–19
The target population in the current study was difficult to
treat because it included severe cases of long-standing ME after
cataract surgery that had failed to respond to previous wide
range of treatment options including oral CAIs, topical
combination therapy with NSAIDs and corticosteroids, as well
as intravitreal treatment, most commonly intravitreal injection
of the corticosteroid TA or the anti-VEGF therapy. The mean
duration of CME before treatment with Ozurdex (Allergan,
Inc.) was 9.1 months (range, 6–13 months).
The treatment approach for ME has been dynamic. Over the
past decades, corticosteroids have raised interest in the
treatment of ME because of their anti-inflammatory effects
and because they inhibit VEGF synthesis and reduce vascular
permeability. Nonetheless, due safety concerns34 (i.e., the risk
of IOP elevation and cataract progression) in recent years, the
use of corticosteroids has been drastically reduced in most
developed countries. Recently, the safety profile of Ozurdex
(Allergan, Inc.), which is currently approved for the treatment
of retinal vein occlusion, was addressed in GENEVA study.14 In
the present series, no major side effects were recorded.
FIGURE 2. Mean changes from baseline BCVA in the study eye.
FIGURE 1. Mean changes from baseline foveal thickness in the study
eye.
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Dexamethasone intravitreal implants were well tolerated and
no anecdotal IOP elevation was observed throughout the study.
Four patients had undergone a pars plana vitrectomy before
entering the current study. The improvement in FT and BCVA
seen in this sample was similar to the improvement seen in the
remaining nonvitrectomized patients. The results of the
present study demonstrate that a dexamethasone implant
may be an effective treatment for pseudophakic CME in
vitrectomized patients, even in severe cases that have failed to
respond to previous therapies. Our data are consistent with
those from a recent analysis in an earlier publication addressing
this issue.19 Advantages of dexamethasone implants over
intravitreal TA in vitrectomized eyes include a longer duration
of action and absence of postinjection ‘‘visual clouding’’ and
floater-like symptoms.
So far, a literature review indicates that the single-injection
of the implant is well tolerated and produces meaningful
improvements in ME and visual acuity that persist through 6
months. However, future longer-term trials are needed to
evaluate the efficacy and safety data in patients who receive
multiple injections.
Our study has several limitations—being a short-term, open-
label, uncontrolled, and retrospective—that preclude any
estimation of the long-term efficacy or safety of intravitreal
Ozurdex (Allergan, Inc.). A significant limitation of this study is
that it included only a relatively small number of patients (nine
eyes) and was not powered to show statistically significant
between-group differences.
Nevertheless, the findings of the present study suggest that
the dexamethasone implant Ozurdex (Allergan, Inc.) may be a
promising new treatment option for patients with recalcitrant
macular edema resulting from Irvine-Gass syndrome and
support further investigation of its clinical value in this patient
population.
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